Kezar Life Sciences Inc

KZR · NASDAQ

Research and Development in Biotechnology · US

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

Market Data

Price $7.13 +0.13 (+1.86%)

Market Cap$51M

P/E Ratio—

EPS$—

52W High$7.45

52W Low$3.53

Beta0.50

Data from Finnhub · Updated Mar 11, 2026